Home » Stocks » CLNN

Clene, Inc. (CLNN)

Stock Price: $7.30 USD 0.32 (4.58%)
Updated May 14, 2021 4:00 PM EDT - Market closed
Market Cap 434.89M
Revenue (ttm) 419,000
Net Income (ttm) -58.86M
Shares Out 59.57M
EPS (ttm) -1.68
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 14
Last Price $7.30
Previous Close $6.98
Change ($) 0.32
Change (%) 4.58%
Day's Open 7.07
Day's Range 7.00 - 7.47
Day's Volume 43,844
52-Week Range 6.23 - 16.50

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Interim Phase 2 data indicate that CNM-Au8 has a homeostatic effect on brain bioenergetics and support its potential to drive meaningful neurological functional improvements in MS patients

5 days ago - GlobeNewsWire

IP portfolio now totals over 160 patents issued, allowed, and pending IP portfolio now totals over 160 patents issued, allowed, and pending

2 weeks ago - GlobeNewsWire

Interim Phase 2 data indicate that CNM-Au8 has a homeostatic effect on brain bioenergetics

1 month ago - GlobeNewsWire

SALT LAKE CITY, March 10, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmace...

2 months ago - GlobeNewsWire

World's first ALS platform trial led by Mass General Hospital and conducted at NEALS centers throughout the United States is a registration trial World's first ALS platform trial led by Mass General Hos...

2 months ago - GlobeNewsWire

SALT LAKE CITY, March 03, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) today announced that its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-...

2 months ago - GlobeNewsWire

Clene Inc (NASDAQ: CLNN) has reported updated blinded interim data from the VISIONARY-MS Phase 2 study evaluating the efficacy and safety of lead drug candidate, CNM-Au8, in multiple sclerosis. The anal...

2 months ago - Benzinga

SALT LAKE CITY, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) today announced that its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-s...

2 months ago - GlobeNewsWire

SALT LAKE CITY, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceu...

2 months ago - GlobeNewsWire

SALT LAKE CITY, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) today announced that its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-s...

3 months ago - GlobeNewsWire

One Wall Street analyst has high hopes for the biopharmaceutical company.

3 months ago - The Motley Fool

Clene is a clinical-stage biopharmaceutical company focused on the development of unique therapeutics for neurodegenerative diseases. Clene has innovated a novel nanotechnology drug platform for the dev...

Other stocks mentioned: TOTA
4 months ago - GlobeNewsWire

About CLNN

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean surfaced nanotechnology (CSN) therapeutics. The company has a nanotechnology drug suspension; and engages in the development and commercialization of dietary supplements. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2 study for the treatment of stable multiple sclerosis; a Phase 2 biomarker study in Parkinson's; and Phase 2 and Phase 3 trials to investigate the potenti... [Read more...]

Industry
Research and Development in Biotechnology
Founded
2012
Stock Exchange
NASDAQ
Ticker Symbol
CLNN
Full Company Profile

Financial Performance

Financial Statements